Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL ‐Related Disorders: A Cross‐Sectional Caregiver Survey Analysis
American Journal of Medical Genetics Part A · 2026
DOI: 10.1002/ajmg.a.64216 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2026. Verfasst von Amanda Piring und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Science Institute, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Puberty, Puberty, Precocious. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, ASXL Rare Research Endowment Foundation, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Limited studies have been conducted on pubertal development in populations with pre‐existing medical conditions. More than 20‐fold increased risk of early puberty has been reported in neurodevelopmental disorders; however, this is a heterogeneous group. There have been limited past studies examining the timing, duration, or characteristics of pubertal or menstrual cycle development in patients with ASXL‐related disorders. This study aimed to gather empirical cross‐sectional parent survey data regarding pubertal development in adolescents diagnosed with Bohring‐Opitz syndrome (BOS) ( ASXL1 ), Shashi‐Pena syndrome (SPS) ( ASXL2 ), or Bainbridge‐Ropers syndrome (BRS) ( ASXL3 ). Our findings showed evidence for parental and perceived provider concern for premature pubarche and possible precocious puberty (PP) in BOS ( ASXL1 ) males and females. Findings between the BOS ( ASXL1 ) and BRS ( ASXL3 ) individuals differed, representing distinct pubertal phenotypes within these populations. Notable trends toward premature development may warrant a low threshold for pediatric endocrinological evaluation in this population. The characterization and description of a pubertal profile for the ASXL‐related syndromes can help inform providers and parents when navigating this stage of development. Our study findings also highlight the need for prospective natural history studies to further define the contribution of pubertal development to the ASXL disorders phenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical and Translational Science Institute, University of California, Los Angeles, California, USA.
- Department of Pediatrics, Division of Endocrinology, University of California, Los Angeles, California, USA.
- Miller Children's and Women's Hospital, Long Beach, California, USA.
- Department of Urology, Division of Clinical Genetics, University of California, Los Angeles, California, USA.
- Department of Medicine Statistics Core, University of California, Los Angeles, California, USA.
- Department of Human Genetics, Division of Clinical Genetics, University of California, Los Angeles, California, USA.
ORCID-Profile: Amanda Piring
Förderung
- NCATS NIH HHS
- ASXL Rare Research Endowment Foundation
- National Center for Advancing Translational Sciences
Zitieren
APA
Piring, A., Hicks, R., Sloan, J., Ramires-Sanchez, E., & Russell, B. E. (2026). Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL ‐Related Disorders: A Cross‐Sectional Caregiver Survey Analysis. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64216
Vancouver
Piring A, Hicks R, Sloan J, Ramires-Sanchez E, Russell BE. Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL ‐Related Disorders: A Cross‐Sectional Caregiver Survey Analysis. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.64216
BibTeX
@article{Piring2026,
author = {Piring, Amanda and Hicks, Rebecca and Sloan, Julia and Ramires-Sanchez, Estefania and Russell, Bianca E},
title = {Assessing Pubertal Timing, Duration, and Related Characteristics in ASXL ‐Related Disorders: A Cross‐Sectional Caregiver Survey Analysis},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
doi = {10.1002/ajmg.a.64216}
}
EUVIMED